BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vescovo T, Refolo G, Vitagliano G, Fimia GM, Piacentini M. Molecular mechanisms of hepatitis C virus-induced hepatocellular carcinoma. Clin Microbiol Infect. 2016;22:853-861. [PMID: 27476823 DOI: 10.1016/j.cmi.2016.07.019] [Cited by in Crossref: 73] [Cited by in F6Publishing: 65] [Article Influence: 12.2] [Reference Citation Analysis]
Number Citing Articles
1 Ngo MT, Jeng HY, Kuo YC, Diony Nanda J, Brahmadhi A, Ling TY, Chang TS, Huang YH. The Role of IGF/IGF-1R Signaling in Hepatocellular Carcinomas: Stemness-Related Properties and Drug Resistance. Int J Mol Sci 2021;22:1931. [PMID: 33669204 DOI: 10.3390/ijms22041931] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Lledó G, Benítez-Gutiérrez L, Arias A, Requena S, Cuervas-Mons V, de Mendoza C. Benefits of hepatitis C cure with antivirals: why test and treat? Future Microbiol 2019;14:425-35. [PMID: 30900911 DOI: 10.2217/fmb-2019-0041] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Mira C, Yepes JO, Henao LF, Montoya Guzmán M, Navas M. EXPRESIÓN DE LA PROTEÍNA CORE DEL VIRUS DE LA HEPATITIS C EN CÉLULAS HEPG2 USANDO EL VIRUS DEL BOSQUE DE SEMLIKI. Acta biol Colomb 2020;26:72-80. [DOI: 10.15446/abc.v26n1.79365] [Reference Citation Analysis]
4 Mabrouk NMK, Elkaffash DM, Abdel-Hadi M, Abdelmoneim SE, Saad ElDeen S, Gewaifel G, Elella KA, Osman M, Baddour N. Identification of the possible therapeutic targets in the insulin-like growth factor 1 receptor pathway in a cohort of Egyptian hepatocellular carcinoma complicating chronic hepatitis C type 4. Drug Target Insights 2020;14:1-11. [PMID: 33132693 DOI: 10.33393/dti.2020.1548] [Reference Citation Analysis]
5 Itami-Matsumoto S, Hayakawa M, Uchida-Kobayashi S, Enomoto M, Tamori A, Mizuno K, Toyoda H, Tamura T, Akutsu T, Ochiya T, Kawada N, Murakami Y. Circulating Exosomal miRNA Profiles Predict the Occurrence and Recurrence of Hepatocellular Carcinoma in Patients with Direct-Acting Antiviral-Induced Sustained Viral Response. Biomedicines 2019;7:E87. [PMID: 31684167 DOI: 10.3390/biomedicines7040087] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
6 Ding D, Huang H, Li Q, Yu W, Wang C, Ma H, Wu J, Dang Y, Yu L, Jiang W. NF90 stabilizes cyclin E1 mRNA through phosphorylation of NF90-Ser382 by CDK2. Cell Death Discov 2020;6:3. [PMID: 32123579 DOI: 10.1038/s41420-020-0236-9] [Reference Citation Analysis]
7 Qu B, Brown RJP. Strategies to Inhibit Hepatitis B Virus at the Transcript Level. Viruses 2021;13:1327. [PMID: 34372533 DOI: 10.3390/v13071327] [Reference Citation Analysis]
8 Alkhatib M, Di Maio VC, De Murtas V, Polilli E, Milana M, Teti E, Fiorentino G, Calvaruso V, Barbaliscia S, Bertoli A, Scutari R, Carioti L, Cento V, Santoro MM, Orro A, Maida I, Lenci I, Sarmati L, Craxì A, Pasquazzi C, Parruti G, Babudieri S, Milanesi L, Andreoni M, Angelico M, Perno CF, Ceccherini-Silberstein F, Svicher V, Salpini R, On Behalf Of Hirma Hepatocarcinoma Innovative Research MArkers And Fondazione Vironet C Hcv Virology Italian Resistance. Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b. Viruses 2021;13:743. [PMID: 33922732 DOI: 10.3390/v13050743] [Reference Citation Analysis]
9 Chandimali N, Koh H, Kim J, Lee J, Park YH, Sun HN, Kwon T. BRM270 targets cancer stem cells and augments chemo-sensitivity in cancer. Oncol Lett 2020;20:103. [PMID: 32831922 DOI: 10.3892/ol.2020.11964] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Jindal A, Thadi A, Shailubhai K. Hepatocellular Carcinoma: Etiology and Current and Future Drugs. J Clin Exp Hepatol 2019;9:221-32. [PMID: 31024205 DOI: 10.1016/j.jceh.2019.01.004] [Cited by in Crossref: 62] [Cited by in F6Publishing: 66] [Article Influence: 20.7] [Reference Citation Analysis]
11 Navas MC, Glaser S, Dhruv H, Celinski S, Alpini G, Meng F. Hepatitis C Virus Infection and Cholangiocarcinoma: An Insight into Epidemiologic Evidences and Hypothetical Mechanisms of Oncogenesis. Am J Pathol 2019;189:1122-32. [PMID: 30953604 DOI: 10.1016/j.ajpath.2019.01.018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
12 Dash S, Aydin Y, Widmer KE, Nayak L. Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment. J Hepatocell Carcinoma 2020;7:45-76. [PMID: 32346535 DOI: 10.2147/JHC.S221187] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
13 Niedźwiedzka-Rystwej P, Grywalska E, Hrynkiewicz R, Wołącewicz M, Becht R, Roliński J. The Double-Edged Sword Role of Viruses in Gastric Cancer.Cancers (Basel). 2020;12. [PMID: 32599870 DOI: 10.3390/cancers12061680] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Zhang C, Wang XM, Li SR, Twelkmeyer T, Wang WH, Zhang SY, Wang SF, Chen JZ, Jin X, Wu YZ, Chen XW, Wang SD, Niu JQ, Chen HR, Tang H. NKG2A is a NK cell exhaustion checkpoint for HCV persistence. Nat Commun 2019;10:1507. [PMID: 30944315 DOI: 10.1038/s41467-019-09212-y] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 15.7] [Reference Citation Analysis]
15 Gal-tanamy M. Multi-omic Analyses Reveal Complex Interactions Between HCV and Hepatocytes Demonstrating That the Red Queen Is Up and Running. Gastroenterology 2019;157:300-2. [DOI: 10.1053/j.gastro.2019.06.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
16 Sze A, Olagnier D, Hadj SB, Han X, Tian XH, Xu HT, Yang L, Shi Q, Wang P, Wainberg MA, Wu JH, Lin R. Sophoraflavenone G Restricts Dengue and Zika Virus Infection via RNA Polymerase Interference. Viruses 2017;9:E287. [PMID: 28972551 DOI: 10.3390/v9100287] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
17 Luo Y, Zhang Y, Wang D, Shen D, Che YQ. Eradication of Hepatitis C Virus (HCV) Improves Survival of Hepatocellular Carcinoma Patients with Active HCV Infection - A Real-World Cohort Study. Cancer Manag Res 2020;12:5323-30. [PMID: 32753950 DOI: 10.2147/CMAR.S254580] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Ippolito G, Antonelli G. Emerging issues on hepatitis C virus infection after the introduction of the Directly Acting Antivirals. Clin Microbiol Infect 2016;22:824-5. [PMID: 27863749 DOI: 10.1016/j.cmi.2016.10.016] [Reference Citation Analysis]
19 Christy SM, Reich RR, Rathwell JA, Vadaparampil ST, Isaacs-Soriano KA, Friedman MS, Roetzheim RG, Giuliano AR. Using the Electronic Health Record to Characterize the Hepatitis C Virus Care Cascade. Public Health Rep 2021;:333549211005812. [PMID: 33831316 DOI: 10.1177/00333549211005812] [Reference Citation Analysis]
20 Axley P, Ahmed Z, Ravi S, Singal AK. Hepatitis C Virus and Hepatocellular Carcinoma: A Narrative Review. J Clin Transl Hepatol. 2018;6:79-84. [PMID: 29607308 DOI: 10.14218/jcth.2017.00067] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 8.8] [Reference Citation Analysis]
21 Shafaati M, Jamalidoust M, Kargar M, Arefian E, Kafilzadeh F. Downregulation of hepatitis C virus replication by miR-196a using lentiviral vectors. Microbiol Immunol 2021;65:161-70. [PMID: 33470443 DOI: 10.1111/1348-0421.12875] [Reference Citation Analysis]
22 Vescovo T, Refolo G, Manuelli MC, Tisone G, Piacentini M, Fimia GM. The Impact of Mevastatin on HCV Replication and Autophagy of Non-Transformed HCV Replicon Hepatocytes Is Influenced by the Extracellular Lipid Uptake. Front Pharmacol 2019;10:718. [PMID: 31316383 DOI: 10.3389/fphar.2019.00718] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
23 Suresh D, Srinivas AN, Kumar DP. Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease. Front Oncol 2020;10:601710. [PMID: 33330100 DOI: 10.3389/fonc.2020.601710] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
24 Ghosh S, Chakraborty J, Goswami A, Bhowmik S, Roy S, Ghosh A, Dokania S, Kumari P, Datta S, Chowdhury A, Bhattacharyya SN, Chatterjee R, Banerjee S. A novel microRNA boosts hyper-β-oxidation of fatty acids in liver by impeding CEP350-mediated sequestration of PPARα and thus restricts chronic hepatitis C. RNA Biol 2020;17:1352-63. [PMID: 32507013 DOI: 10.1080/15476286.2020.1768353] [Reference Citation Analysis]
25 Khatun M, Ray R, Ray RB. Hepatitis C virus associated hepatocellular carcinoma. Adv Cancer Res 2021;149:103-42. [PMID: 33579422 DOI: 10.1016/bs.acr.2020.10.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Liu H, Li B. The functional role of exosome in hepatocellular carcinoma. J Cancer Res Clin Oncol 2018;144:2085-95. [PMID: 30062486 DOI: 10.1007/s00432-018-2712-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
27 Li S, Liu R, Pan Q, Wang G, Cheng D, Yang J, Chen H, Xu G. De novo lipogenesis is elicited dramatically in human hepatocellular carcinoma especially in hepatitis C virus-induced hepatocellular carcinoma. MedComm (2020) 2020;1:178-87. [PMID: 34766116 DOI: 10.1002/mco2.15] [Reference Citation Analysis]
28 Unfried JP, Fortes P. LncRNAs in HCV Infection and HCV-Related Liver Disease. Int J Mol Sci 2020;21:E2255. [PMID: 32214045 DOI: 10.3390/ijms21062255] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
29 Jing Z, Ye X, Ma X, Hu X, Yang W, Shi J, Chen G, Gong L. SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR-23b-3p via sponging EGR1 in hepatocellular carcinoma. Cancer Med 2020;9:4324-38. [PMID: 32324343 DOI: 10.1002/cam4.3020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
30 Leibovici L. Are we making an impact? Clin Microbiol Infect 2017;23:783-4. [PMID: 28782650 DOI: 10.1016/j.cmi.2017.07.027] [Reference Citation Analysis]
31 Kamal A, Elsheaita A, Abdelnabi M. Association between direct-acting antiviral agents in hepatitis C virus treatment and hepatocellular carcinoma occurrence and recurrence: The endless debate. World J Clin Cases 2022; 10(6): 1764-1774 [DOI: 10.12998/wjcc.v10.i6.1764] [Reference Citation Analysis]
32 Liu M, Shi J, Mou T, Wang Y, Wu Z, Shen A. Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis. J Gastroenterol Hepatol. 2020;35:1277-1287. [PMID: 32052876 DOI: 10.1111/jgh.15010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
33 El-Khazragy N, Elshimy AA, Hassan SS, Shaaban MH, Bayoumi AH, El Magdoub HM, Ghozy S, Gaballah A, Aboelhussein MM, Abou Gabal HH, Bannunah AM, Mansy AE. lnc-HOTAIR predicts hepatocellular carcinoma in chronic hepatitis C genotype 4 following direct-acting antivirals therapy. Mol Carcinog 2020;59:1382-91. [PMID: 33074585 DOI: 10.1002/mc.23263] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Li S, Saviano A, Erstad DJ, Hoshida Y, Fuchs BC, Baumert T, Tanabe KK. Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges. J Clin Med 2020;9:E3817. [PMID: 33255794 DOI: 10.3390/jcm9123817] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
35 Wang ZX, Zhou CX, Calderón-Mantilla G, Petsalaki E, He JJ, Song HY, Elsheikha HM, Zhu XQ. iTRAQ-Based Global Phosphoproteomics Reveals Novel Molecular Differences Between Toxoplasma gondii Strains of Different Genotypes. Front Cell Infect Microbiol 2019;9:307. [PMID: 31508380 DOI: 10.3389/fcimb.2019.00307] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
36 Klöhn M, Schrader JA, Brüggemann Y, Todt D, Steinmann E. Beyond the Usual Suspects: Hepatitis E Virus and Its Implications in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:5867. [PMID: 34831021 DOI: 10.3390/cancers13225867] [Reference Citation Analysis]
37 Marangon CG, de Bitencorte JT, Michita RT, Lunge VR, Dos Santos DC, Álvares-da-Silva MR, Simon D. Association between MICA rs2596542 Polymorphism with the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients. Pathol Oncol Res 2020;26:1519-25. [PMID: 31471884 DOI: 10.1007/s12253-019-00738-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
38 Qian S, Golubnitschaja O, Zhan X. Chronic inflammation: key player and biomarker-set to predict and prevent cancer development and progression based on individualized patient profiles. EPMA J 2019;10:365-81. [PMID: 31832112 DOI: 10.1007/s13167-019-00194-x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 19.0] [Reference Citation Analysis]
39 Cha S, Park I, Jang KL. Hepatitis C virus core protein activates proteasomal activator 28 gamma to downregulate p16 levels via ubiquitin-independent proteasomal degradation.Heliyon. 2021;7:e06134. [PMID: 33553768 DOI: 10.1016/j.heliyon.2021.e06134] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Hemming AW. Biliary Tract and Primary Liver Tumors. Surgical Oncology Clinics of North America 2019;28:519-38. [DOI: 10.1016/j.soc.2019.06.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
41 Mostafa AM, Saafan HA, Al-Tawashi AS, Kasem MH, Alaa AM, Eltobgy MM, Moubarak AS, Gharib MM, Awwad MA, Omar HM, El-Derany MO. Interleukin-17 haplotyping predicts hepatocellular carcinoma in sofosbuvir, pegylated interferon-alpha-2a & ribavirin treated chronic hepatitis C patients. Virus Res 2021;292:198226. [PMID: 33171166 DOI: 10.1016/j.virusres.2020.198226] [Reference Citation Analysis]
42 Mostafa WSEM, Al-Dahr MHS, Omran DAH, Abdullah ZF, Elmasry SH, Ibrahim MN. Influence of some methylated hepatocarcinogenesis-related genes on the response to antiviral therapy and development of fibrosis in chronic hepatitis C patients. Clin Mol Hepatol 2020;26:60-9. [PMID: 31630500 DOI: 10.3350/cmh.2019.0051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
43 Ahmed NAF, Ali ASH, El Baz RA, El-zayyadi IAE. IL-28B single nucleotide polymorphism as a predictor of hepatocellular carcinoma after treatment of chronic hepatitis C patients with direct acting antivirals. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00102-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Ng A. Hepatocellular carcinoma recurrence after directly-acting antiviral therapy: caution with hepatitis C. European Journal of Gastroenterology & Hepatology 2021;33:e1091-2. [DOI: 10.1097/meg.0000000000002193] [Reference Citation Analysis]
45 Ríos-Ocampo WA, Navas MC, Faber KN, Daemen T, Moshage H. The cellular stress response in hepatitis C virus infection: A balancing act to promote viral persistence and host cell survival. Virus Res 2019;263:1-8. [PMID: 30599163 DOI: 10.1016/j.virusres.2018.12.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
46 El-Mowafy M, Elgaml A, El-Mesery M, Sultan S, Ahmed TAE, Gomaa AI, Aly M, Mottawea W. Changes of Gut-Microbiota-Liver Axis in Hepatitis C Virus Infection. Biology (Basel) 2021;10:55. [PMID: 33451143 DOI: 10.3390/biology10010055] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
47 Alkharsah KR. VEGF Upregulation in Viral Infections and Its Possible Therapeutic Implications. Int J Mol Sci. 2018;19. [PMID: 29865171 DOI: 10.3390/ijms19061642] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 7.8] [Reference Citation Analysis]
48 Sheikh M, Bokharaei-Salim F, Monavari SH, Ataei-Pirkooh A, Esghaei M, Moradi N, Babaei R, Fakhim A, Keyvani H. Molecular diagnosis of occult hepatitis C virus infection in Iranian injection drug users. Arch Virol. 2019;164:349-357. [PMID: 30390150 DOI: 10.1007/s00705-018-4066-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
49 Chen G, Zhang W, Ben Y. Identification of Key Regulators of Hepatitis C Virus-Induced Hepatocellular Carcinoma by Integrating Whole-Genome and Transcriptome Sequencing Data. Front Genet 2021;12:741608. [PMID: 34567091 DOI: 10.3389/fgene.2021.741608] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Refolo G, Ciccosanti F, Di Rienzo M, Basulto Perdomo A, Romani M, Alonzi T, Tripodi M, Ippolito G, Piacentini M, Fimia GM. Negative Regulation of Mitochondrial Antiviral Signaling Protein-Mediated Antiviral Signaling by the Mitochondrial Protein LRPPRC During Hepatitis C Virus Infection. Hepatology 2019;69:34-50. [PMID: 30070380 DOI: 10.1002/hep.30149] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
51 Mui UN, Haley CT, Tyring SK. Viral Oncology: Molecular Biology and Pathogenesis. J Clin Med 2017;6:E111. [PMID: 29186062 DOI: 10.3390/jcm6120111] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 9.6] [Reference Citation Analysis]
52 Ndako JA, Owolabi AO, Olisa JA, Akinwumi JA, Dojumo VT, Olatinsu O, Adebayo BA. Studies on the prevalence of Hepatitis C virus infection in diabetic patients attending a tertiary health-care facility South-west Nigeria. BMC Infect Dis 2020;20:664. [PMID: 32907538 DOI: 10.1186/s12879-020-05388-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Zamaraev AV, Zhivotovsky B, Kopeina GS. Viral Infections: Negative Regulators of Apoptosis and Oncogenic Factors. Biochemistry (Mosc) 2020;85:1191-201. [PMID: 33202204 [PMID: 33202204 DOI: 10.1134/s0006297920100077] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
54 Amr KS, Elmawgoud Atia HA, Elazeem Elbnhawy RA, Ezzat WM. Early diagnostic evaluation of miR-122 and miR-224 as biomarkers for hepatocellular carcinoma. Genes Dis 2017;4:215-21. [PMID: 30258925 DOI: 10.1016/j.gendis.2017.10.003] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 7.6] [Reference Citation Analysis]
55 Masetti C, Lionetti R, Lupo M, Siciliano M, Giannelli V, Ponziani FR, Teti E, Dell'unto C, Francioso S, Brega A, Montalbano M, Visco-comandini U, Taibi C, Galati G, Vespasiani Gentilucci U, Picardi A, Andreoni M, Pompili M, Pellicelli AM, D'offizi G, Gasbarrini A, De Santis A, Angelico M. Lack of reduction in serum alpha-fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virus-related cirrhosis. J Viral Hepat 2018;25:1493-500. [DOI: 10.1111/jvh.12982] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
56 Romano A, Angeli P, Piovesan S, Noventa F, Anastassopoulos G, Chemello L, Cavalletto L, Gambato M, Russo FP, Burra P, Vincenzi V, Scotton PG, Panese S, Tempesta D, Bertin T, Carrara M, Carlotto A, Capra F, Carolo G, Scroccaro G, Alberti A. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study. J Hepatol. 2018;69:345-352. [PMID: 29551707 DOI: 10.1016/j.jhep.2018.03.009] [Cited by in Crossref: 66] [Cited by in F6Publishing: 67] [Article Influence: 16.5] [Reference Citation Analysis]
57 Maeda N, Maenaka K. The Roles of Matricellular Proteins in Oncogenic Virus-Induced Cancers and Their Potential Utilities as Therapeutic Targets. Int J Mol Sci 2017;18:E2198. [PMID: 29065446 DOI: 10.3390/ijms18102198] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
58 Nguyen LP, Nguyen TTT, Nguyen HC, Pham HT, Han KM, Choi DH, Park EM, Kang SM, Tark D, Lim YS, Hwang SB. Cortactin Interacts with Hepatitis C Virus Core and NS5A Proteins: Implications for Virion Assembly. J Virol 2020;94:e01306-20. [PMID: 32727880 DOI: 10.1128/JVI.01306-20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 González-Aldaco K, Torres-Reyes LA, Ojeda-Granados C, José-Ábrego A, Fierro NA, Román S. Immunometabolic Effect of Cholesterol in Hepatitis C Infection: Implications in Clinical Management and Antiviral Therapy. Ann Hepatol 2018;17:908-19. [PMID: 30600305 DOI: 10.5604/01.3001.0012.7191] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
60 Kang Y, Su G, Sun J, Zhang Y. Activation of the TLR4/MyD88 signaling pathway contributes to the development of human hepatocellular carcinoma via upregulation of IL-23 and IL-17A. Oncol Lett 2018;15:9647-54. [PMID: 29928340 DOI: 10.3892/ol.2018.8586] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
61 Wei J, Wang B, Gao X, Sun D. Prognostic Value of a Novel Signature With Nine Hepatitis C Virus-Induced Genes in Hepatic Cancer by Mining GEO and TCGA Databases. Front Cell Dev Biol 2021;9:648279. [PMID: 34336819 DOI: 10.3389/fcell.2021.648279] [Reference Citation Analysis]
62 Ali MAM, Harmsen WS, Morsy KH, Galal GMK, Therneau TM, Roberts LR. Prognostic utility of systemic inflammatory markers and chronic hepatitis C virus infection status in hepatocellular carcinoma patients treated with local ablation. BMC Cancer 2022;22:221. [PMID: 35227234 DOI: 10.1186/s12885-021-09121-8] [Reference Citation Analysis]
63 Gundala R, Balutia H, Lavanya R, Velayutham R, Roy KK. HCV NS3 serine protease as a drug target for the development of drugs against hepatocellular carcinoma (liver cancer). Cancer-Leading Proteases. Elsevier; 2020. pp. 243-63. [DOI: 10.1016/b978-0-12-818168-3.00009-7] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
64 Irshad M, Gupta P, Irshad K. Molecular basis of hepatocellular carcinoma induced by hepatitis C virus infection. World J Hepatol 2017; 9(36): 1305-1314 [PMID: 29359013 DOI: 10.4254/wjh.v9.i36.1305] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 6.2] [Reference Citation Analysis]
65 Ishida H, Takemura M, Suetsugu A, Naiki T, Tanaka T, Eiichi T, Serrero G, Matsunami H, Yamamoto Y, Saito K. Serum GP88 as a predictive biomarker for hepatocellular carcinoma in patients with viral hepatitis C after direct-acting antiviral agents. Ann Clin Biochem 2021;:45632211036723. [PMID: 34284614 DOI: 10.1177/00045632211036723] [Reference Citation Analysis]
66 Gull N, Arshad F, Naikoo GA, Hassan IU, Pedram MZ, Ahmad A, Aljabali AAA, Mishra V, Satija S, Charbe N, Negi P, Goyal R, Serrano-Aroca Á, Al Zoubi MS, El-Tanani M, Tambuwala MM. Recent Advances in Anticancer Activity of Novel Plant Extracts and Compounds from Curcuma longa in Hepatocellular Carcinoma. J Gastrointest Cancer 2022. [PMID: 35285010 DOI: 10.1007/s12029-022-00809-z] [Reference Citation Analysis]
67 Wu B, Sodji QH, Oyelere AK. Inflammation, Fibrosis and Cancer: Mechanisms, Therapeutic Options and Challenges. Cancers 2022;14:552. [DOI: 10.3390/cancers14030552] [Reference Citation Analysis]
68 Young KG, Haq K, MacLean S, Dudani R, Elahi SM, Gilbert R, Weeratna RD, Krishnan L. Development of a recombinant murine tumour model using hepatoma cells expressing hepatitis C virus nonstructural antigens. J Viral Hepat 2018;25:649-60. [PMID: 29316037 DOI: 10.1111/jvh.12856] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
69 Geisslinger F, Vollmar AM, Bartel K. Cancer Patients Have a Higher Risk Regarding COVID-19 - and Vice Versa? Pharmaceuticals (Basel) 2020;13:E143. [PMID: 32640723 DOI: 10.3390/ph13070143] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
70 Lauletta G, Russi S, Pavone F, Vacca A, Dammacco F. Direct-acting antiviral agents in the therapy of hepatitis C virus-related mixed cryoglobulinaemia: a single-centre experience. Arthritis Res Ther 2017;19:74. [PMID: 28388935 DOI: 10.1186/s13075-017-1280-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
71 Muzica CM, Stanciu C, Huiban L, Singeap AM, Sfarti C, Zenovia S, Cojocariu C, Trifan A. Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end. World J Gastroenterol 2020; 26(43): 6770-6781 [PMID: 33268960 DOI: 10.3748/wjg.v26.i43.6770] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
72 Khalid SS, Abdo AA, Al-Hamoudi W, Alswat K. Association of mitotic checkpoint regulator MAD2L1 with fibrosis progression in chronic hepatitis C patients. Clin Res Hepatol Gastroenterol 2022;:101860. [PMID: 34999251 DOI: 10.1016/j.clinre.2022.101860] [Reference Citation Analysis]
73 Vojtechova Z, Tachezy R. The Role of miRNAs in Virus-Mediated Oncogenesis. Int J Mol Sci 2018;19:E1217. [PMID: 29673190 DOI: 10.3390/ijms19041217] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
74 Vescovo T, Pagni B, Piacentini M, Fimia GM, Antonioli M. Regulation of Autophagy in Cells Infected With Oncogenic Human Viruses and Its Impact on Cancer Development. Front Cell Dev Biol 2020;8:47. [PMID: 32181249 DOI: 10.3389/fcell.2020.00047] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
75 Moon H, Ro SW. MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:3026. [PMID: 34204242 DOI: 10.3390/cancers13123026] [Reference Citation Analysis]
76 Hashempour T, Dehghani B, Musavi Z, Moayedi J, Hasanshahi Z, Sarvari J, Hosseini SY, Hosseini E, Moeini M, Merat S. Impact of IL28 Genotypes and Modeling the Interactions of HCV Core Protein on Treatment of Hepatitis C. Interdiscip Sci 2020;12:424-37. [PMID: 32656614 DOI: 10.1007/s12539-020-00382-8] [Reference Citation Analysis]